九州大学 研究者情報
研究者情報 (研究者の方へ)入力に際してお困りですか?
基本情報 研究活動 教育活動 社会活動
鵜木 元香(うのき もとこ) データ更新日:2020.02.22

准教授 /  生体防御医学研究所 分子機能制御学部門 エピゲノム制御学分野


主な研究テーマ
エピジェネティック制御機構に関わるタンパク質相互作用の研究
キーワード:エピジェネティクス, ヒストン修飾, DNAメチル化, UHRF1, ICF症候群, 癌治療
2010.10~2020.04.
従事しているプロジェクト研究
エピジェネティクス関連遺伝子の変異情報に基づいた腎癌治療
2014.04~2017.03, 代表者:鵜木元香, 九州大学.
ICF症候群発症の分子機構の解明
2011.04~2020.03, 代表者:鵜木元香, 九州大学生体防御医学研究所, 九州大学生体防御医学研究所
ICF症候群の原因遺伝子CDCA7とHELLSの機能解析から、ICF症候群が発症する分子機構を解明する。.
UHRF1が初期発生および生殖細胞形成に果たす役割の解明
2010.10~2020.03, 代表者:鵜木元香, 九州大学生体防御医学研究所, 九州大学生体防御医学研究所.
初期発生に関与するジンクフィンガータンパク質の同定と機能解析
2012.04~2016.03, 代表者:鵜木元香, 九州大学生体防御医学研究所, 九州大学生体防御医学研究所.
新規メチル化DNA結合タンパク質の同定
2011.10~2014.03, 代表者:鵜木元香, 九州大学生体防御医学研究所, 九州大学生体防御医学研究所.
UHRF1複合体に含まれるJMJD6が関わる新規ヒストン修飾についての機能解析
2010.04~2013.03, 代表者:鵜木元香, 九州大学・生体防御医学研究所, 九州大学.
研究業績
主要著書
1. Unoki M, DNA methylation mechanism
Chapter: Recent insights into the mechanisms of de novo and maintenance DNA methylation in mammals
, INTECH, 10.5772/intechopen.89238, 2019.09, [URL].
2. Motoko Unoki, 生まれつきの女王蜂はいない DNAだけでは決まらない遺伝子の使い道, 講談社, 2016.11, [URL].
3. 鵜木 元香, 佐々木 裕之, エピジェネティクスキーワード事典: 第2部-4: 生殖・発生, 羊土社, p.123-129, 2013.11, [URL].
4. 鵜木 元香, 佐々木 裕之, エピジェネティクスの産業応用: 第5章: 生殖細胞形成と個体発生におけるエピジェネティクス , シーエムシー出版, p.78-89 , 2014.04, [URL], エピジェネティクスは、英国の発生学者C. H. Waddingtonが造語した発生学のエピジェネシス(後成説)とジェネティクス(遺伝学)の混成語で、語源が示すように個体発生に重要なクロマチン構造の調節機構である。Waddingtonは発生過程を多数の谷筋のある斜面の風景に例え(エピジェネティックランドスケープ)、頂上にあるボールはどの谷に転がる可能性もあるが、一旦運命決定されるとその谷筋から外れることはなく、これを保証しているのがエピジェネティクスであるという概念を提唱した(図1)。しかし世代から世代へと繰り返される生命のループを考えると、成熟個体は生殖細胞である卵子と精子を作り、それらの受精でできた新しい生命(受精卵〜初期胚)はエピジェネティックランドスケープの山頂に戻らなくてはいけない。このように考えると、エピジェネティクスは一方向性の斜面だけではなく、何度でも元に戻ることができるループも形成しており、元に戻すにはダイナミックなリプログラミングが必要である(図1)。このリプログラミングは生殖細胞形成と個体発生の過程で起こり、哺乳類のエピジェネティックな変化の中で最もダイナミックである。生殖細胞形成過程で起こるリプログラミングは潜在的多能性の獲得やゲノムインプリンティング・X染色体不活性化の書き換えに関わっており、個体発生におけるリプログラミングは初期胚の万能性獲得に重要である。本稿では哺乳類のモデル動物であるマウスを主な対象として、ゲノムインプリンティングとX染色体不活性化について概説し、生殖細胞形成と個体発生におけるエピジェネティックな変化を起こす分子機構について述べる。.
5. Unoki M. et al., Bladder Cancer
Chapter: UHRF1 is a potential molecular marker for diagnosis and prognosis of bladder cancer
, INTECH, DOI: 10.5772/26914, 2011.10, [URL].
6. 鵜木元香, 中村祐輔 , cDNAマイクロアレイを利用した癌抑制遺伝子シグナル伝達経路の研究~PTENを中心に~, 羊土社, Bioベンチャー 7-8月号, 22-26, 2003.06, [URL].
主要原著論文
1. Sharmin Aktar, Hiroyuki Sasaki, Motoko Unoki, Identification of ZBTB24 protein domains and motifs essential for heterochromatin localization and transcriptional activation, Genes to Cells, doi.org/10.1111/gtc.12723, 24, 11, 746-755, 2019.09, [URL].
2. Motoko Unoki, Hironori Funabiki, Guillaume Velasco, Claire Francastel, Hiroyuki Sasaki, CDCA7 and HELLS mutations undermine non-homologous end joining in centromeric instability syndrome, J. Clin. Invest., doi: 10.1172/JCI99751, 129, 1, 78-92, 2019.01, [URL].
3. Shoji Maenohara, Motoko Unoki, Hidehiro Toh, Hiroaki Ohishi, Jafar Sharif, Haruhiko Koseki, Hiroyuki Sasaki, Role of UHRF1 in De Novo DNA Methylation in Oocytes and Maintenance Methylation in Preimplantation Embryos, PLOS Genetics, 10.1371/journal.pgen.1007042. , 13, 10, e1007042, 2017.10, [URL], The methylation of cytosine at CG sites in the mammalian genome is dynamically reprogrammed during gametogenesis and preimplantation development. It was previously shown that oocyte-derived DNMT1 (a maintenance methyltransferase) is essential for maintaining and propagating CG methylation at imprinting control regions in preimplantation embryos. In mammalian somatic cells, hemimethylated-CG-binding protein UHRF1 plays a critical role in maintaining CG methylation by recruiting DNMT1 to hemimethylated CG sites. However, the role of UHRF1 in oogenesis and preimplantation development is unknown. In the present study, we show that UHRF1 is mainly, but not exclusively, localized in the cytoplasm of oocytes and preimplantation embryos. However, smaller amounts of UHRF1 existed in the nucleus, consistent with the expected role in DNA methylation. We then generated oocyte-specific Uhrf1 knockout (KO) mice and found that, although oogenesis was itself unaffected, a large proportion of the embryos derived from the KO oocytes died before reaching the blastocyst stage (a maternal effect). Whole genome bisulfite sequencing revealed that blastocysts derived from KO oocytes have a greatly reduced level of CG methylation, suggesting that maternal UHRF1 is essential for maintaining CG methylation, particularly at the imprinting control regions, in preimplantation embryos. Surprisingly, UHRF1 was also found to contribute to de novo CG and non-CG methylation during oocyte growth: in Uhrf1 KO oocytes, transcriptionally-inactive regions gained less methylation, while actively transcribed regions, including the imprinting control regions, were unaffected. We also found that de novo methylation was defective during the late stage of oocyte growth. To the best of our knowledge, this is the first study to demonstrate the role of UHRF1 in de novo DNA methylation in vivo. Our study reveals multiple functions of UHRF1 during the global epigenetic reprogramming of oocytes and early embryos..
4. Motoko Unoki, Akiko Masuda, Naoshi Dohmae, Kyohei Arita, Masanori Yoshimatsu, Yukiko Iwai, Yoshinori Fukui, Koji Ueda, Ryuji Hamamoto, Masahiro Shirakawa, Hiroyuki Sasaki, Yusuke Nakamura, Lysyl 5-Hydroxylation, a Novel Histone Modification, by Jumonji Domain Containing 6 (JMJD6), J Biol Chem, 10.1074/jbc.M112.433284 , 288, 9, 6053-6062, 2013.03, [URL], JMJD6 is reported to hydroxylate lysyl residues of a splicing factor, U2AF65. In this study, we found that JMJD6 hydroxylates histone lysyl residues. In vitro experiments showed that JMJD6 has a binding affinity to histone proteins and hydroxylates multiple lysyl residues of histone H3 and H4 tails. Using JMJD6 knockout mouse embryos, we revealed that JMJD6 hydroxylates lysyl residues of histones H2A/H2B and H3/H4 in vivo by amino acid composition analysis. 5-hydroxylysine was detected at the highest level in histones purified from murine testis, which expressed JMJD6 at a significantly high level among various tissues examined, and JMJD6 overexpression increased the amount of 5-hydroxylysine in histones in human embryonic kidney 293 cells. These results indicate that histones are additional substrates of JMJD6 in vivo. Because 5-hydroxylation of lysyl residues inhibited N-acetylation and N-methylation by an acetyltransferase and a methyltransferase, respectively, in vitro, histone 5-hydroxylation may have important roles in epigenetic regulation of gene transcription or chromosomal rearrangement..
5. Unoki M, Daigo D, Koinuma J, Tsuchiya E, Hamamoto R, Nakamura Y., UHRF1 is a novel diagnostic marker of lung cancer. , Br. J. Cancer, 10.1038/sj.bjc.6605717, 103, 2, 217-22, 2010.07, [URL], BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide. As the sensitivity and specificity of current diagnostic markers are not perfect, we examined whether ubiquitin-like with PHD and ring finger domains 1 (UHRF1), which is overexpressed in various cancers but not yet examined in lung cancer in large scale, can be a novel diagnostic marker of lung cancer.

METHODS: Immunohistochemical analysis using surgical specimens obtained from 56 US and 322 Japanese patients with lung cancer was performed.

RESULTS: The UHRF1 was stained specifically in the nuclei of cancer cells, but not in the other cells. The UHRF1 expression was observed in all histological types of lung cancer, especially in non-adenocarcinomas (non-ADCs), both in the US and Japanese cases. In 322 Japanese non-small cell lung cancer (NSCLC) cases, UHRF1 expression was associated with the histological type (higher in non-ADCs; P<0.00001), gender (higher in male; P=0.00082), smoking (higher in smokers; P=0.00004), pT factor (higher in advanced stage; P=0.00010), and pN factor (higher in cancers with metastasis in regional lymph nodes; P=0.00018). The UHRF1 expression was also associated with poor prognosis for NSCLC patients (P=0.0364). Although UHRF1 overexpression was associated with these malignant indicators, UHRF1 was detectable in half of lung cancer patients in an early pathological stage.

CONCLUSION: The UHRF1 is overexpressed in various types of lung cancer from early pathological stage. Therefore, detection of UHRF1 expression in tissue specimens by immunohistochemistry can be useful for diagnosis of lung cancer in all pathological stages..
6. Unoki M, Kelly JD, Neal DE, Ponder BAJ, Nakamura Y, Hamamoto R., UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer., Br. J. Cancer, 10.1038/sj.bjc.6605123, 101, 1, 98-106, 2009.07, [URL], BACKGROUND: Bladder cancer is the second most common cancer of the urinary system. Early diagnosis of this tumour and estimation of risk of future progression after initial transuretherial resection have a significant impact on prognosis. Although there are several molecular markers for the diagnosis and prognosis for this tumour, their accuracy is not ideal. Previous reports have shown that UHRF1 (ubiquitin-like with PHD and ring-finger domains 1) is essential for cellular proliferation. In this study, we examined whether UHRF1 can be a novel molecular marker of bladder cancer.

METHODS: We performed real-time TaqMan quantitative reverse transcription-PCR and immunohistochemistry to examine expression levels of UHRF1 in bladder and kidney cancers.

RESULTS: Significant overexpression of UHRF1 was observed in bladder cancer. The overexpression was correlated with the stage and grade of the cancer. Although UHRF1 expression in muscle-invasive cancer was greater than in non-invasive (pTa) or superficially invasive (pT1) cancers, UHRF1 could still be detected by immunohistochemistry in these early-stage cancers. Overexpression of UHRF1 in bladder cancer was associated with increased risk of progression after transurethral resection. High expression of UHRF1 in kidney cancer was also observed. But the increased levels of UHRF1 in kidney cancer were less significant compared with those in bladder cancer.

CONCLUSION: Our result indicates that an immunohistochemistry-based UHRF1 detection in urine sediment or surgical specimens can be a sensitive and cancer-specific diagnostic and/or prognosis method, and may greatly improve the current diagnosis based on cytology..
7. Unoki M, Kumamoto K, Robles AI,Shen JC,Zheng ZM, Harris CC., A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis., FEBS Letters, 10.1016/j.febslet.2008.10.024, 582, 28, 3868-74, 2008.11, [URL], We identified a novel inhibitor of growth family member 2 (ING2) isoform, ING2b, which shares exon 2 with ING2a, but lacks the N-terminal p53 binding region. Contrary to ING2a, ING2b's promoter has no p53 binding sites. Consistently, activation of p53 led to suppression of ING2a, leaving ING2b unaffected. Through isoform-specific targeting, we showed that ING2a knockdown suppressed cell growth only in the presence of p53, ING2b knockdown had no effect on cell growth, and knockdown of both induced cell cycle arrest and apoptosis independently of p53. ING2a and ING2b have compensatory roles that protect cells from cell cycle arrest and apoptosis and may be involved in development of chemotherapeutic resistance..
8. Unoki M, Bronner C, Mousli M., A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1., Radiat Res., 10.1667/RR1209.1, 169, 2, 240-4, 2008.02, [URL], ICBP90/UHRF1, which is overexpressed in cancer cells and is down-regulated by p53, possesses a methylated CpG binding affinity and binds to the methylated promoters of tumor suppressor genes in cancer cells with HDAC1 and DNMT1, suggesting suppression of these genes and maintenance of methylation status which leads to carcinogenesis. Recently, it was reported that the human homolog of Np95 is different from ICBP90 but not from UHRF1. Because UHRF1 is the gene symbol of ICBP90, the claim is a little confusing; that is, UHRF1 and ICBP90 are identical. Because the previously published genomic structure of the ICBP90 gene needed to be revised and the registered ICBP90 sequence (AF129507) contains two rare polymorphisms or sequence errors, we think that confusion could occur. Here we show the revised ICBP90 gene structure and 366 polymorphisms in this gene. Our conclusion is that the human homolog of Np95 is ICBP90, whose gene symbol is UHRF1..
9. Unoki M, Shen JC, Zheng ZM, Harris, CC., Novel splice variants of ING4 and their possible roles in regulation of cell growth and motility. , J Biol Chem., 10.1074/jbc.M606296200, 281, 45, 34677-86, 2006.11, [URL], The ING4 gene is a candidate tumor suppressor gene that functions in cell proliferation, contact inhibition, and angiogenesis. We identified three novel splice variants of ING4 with differing activities in controlling cell proliferation, cell spreading, and cell migration. ING4_v1 (the longest splice variant), originally identified as ING4, encodes an intact nuclear localization signal (NLS), whereas the other three splice variants (ING4_v2, ING4_v3, and ING4_v4) lack the full NLS, resulting in increased cytoplasmic localization of these proteins. We found that one of the three ING4 variants, ING4_v2, is expressed at the same level as the original ING4 (ING4_v1), suggesting that ING4 variants may have significant biological functions. Growth suppressive effects of the variants that have a partial NLS (ING4_v2 and ING4_v4) were attenuated by a weaker effect of the variants on p21(WAF1) promoter activation. ING4_v4 lost cell spreading and migration suppressive effects; on the other hand, ING4_v2 retained a cell migration suppressive effect but lost a cell spreading suppressive effect. Therefore, ING4_v2, which localized primarily into cytoplasm, might have an important role in the regulation of cell migration. We also found that ING4_v4 played dominant-negative roles in the induction of p21(WAF1) promoter activation and in the suppression of cell motility by ING4_v1. In addition, ING4 variants had different binding affinities to two cytoplasmic proteins, protein-tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha1, and G3BP2a. Understanding the functions of the four splice variants may aid in defining their roles in human carcinogenesis..
10. Unoki M, Nishidate T, Nakamura Y., ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain., Oncogene, 10.1038/sj.onc.1208053, 23, 46, 7601-10., 2004.10, [URL], ICBP90, inverted CCAAT box-binding protein of 90 kDa, has been reported as a regulator of topoisomerase IIalpha expression. We present evidence here that ICBP90 binds to methyl-CpG when at least one symmetrically methylated-CpG dinucleotides is presented as its recognition sequence. A SET and RING finger-associated (SRA) domain accounts for the high binding affinity of ICBP90 for methyl-CpG dinucleotides. This protein constitutes a complex with HDAC1 also via its SRA domain, and bound to methylated promoter regions of various tumor suppressor genes, including p16INK4Aand p14ARF, in cancer cells. It has been reported that expression of ICBP90 was upregulated by E2F-1, and we confirmed that the upregulation was caused by binding of E2F-1 to the intron1 of ICBP90, which contains two E2F-1-binding motifs. Our data also revealed accumulation of ICBP90 in breast-cancer cells, where it might suppress expression of tumor suppressor genes through deacetylation of histones after recruitment of HDAC1. The data reported here suggest that ICBP90 is involved in cell proliferation by way of methylation-mediated regulation of certain genes..
11. Unoki M, Nakamura Y., Methylation at CpG-islands in intron1 of EGR2 confers enhancer-like activity., FEBS Lett., 10.1016/S0014-5793(03)01092-5, 554, 1-2, 67-72, 2003.11, [URL], We previously demonstrated several lines of evidence indicating that early growth response 2 (EGR2) functions as a tumor suppressor, partly on the basis that its expression was often decreased in human tumors and cancer cell lines. Here we report a possible molecular mechanism to account for down-regulation of EGR2 in tumor cells. Although no genetic mutations in the gene or alterations in methylation status of its promoter were detected, we found a high degree of methylation at CpG islands in intron 1 of EGR2 in cell lines that were expressing this gene at a high level. Moreover, reporter gene experiments revealed that methylated intron 1 had somehow conferred enhancer-like activity. The data imply the existence of a previously unsuspected mechanism of gene expression regulation..
12. Unoki M, Okutsu J, Nakamura Y. , Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia., Int J Oncol., 22, 6, 1217-23, 2003.06, [URL], To elucidate mechanisms leading to acute myelogenous leukemia (AML), to find sensitive markers and novel targets for drug therapy, and to allow choice of suitable chemotherapy for each affected individual, we previously compared expression of mRNA from mononuclear cells of AML patients with that of normal controls using a cDNA microarray. Data from that study identified many genes that were commonly up- or down-regulated in AML cells. Of these, we report here the identification of a novel gene whose expression was increased in 27 (93%) of the 29 AML cases whose PBMC preparations include >70% leukemia cells. The gene product, localized in nuclei, showed several characteristics of transcription factors: five zinc-finger domains, a leucine zipper, and several nuclear localization signals. Its 92.5% identity in amino-acid sequence to the murine penta zinc finger protein (mPZf; gene symbol Zfp91), led us to term it ZFP91. Anti-sense oligonucleotides inhibited expression of ZFP91, suppressed cell growth, and induced apoptosis. Our results suggest that ZFP91 is likely to play an important role in cell proliferation and/or anti-apoptosis, and may serve as a molecular marker for AML..
13. Unoki M, Nakamura Y., EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK., Oncogene, 10.1038/sj.onc.1206222, 22, 14, 2172-85., 2003.04, [URL], EGR2 plays a key role in the PTEN-induced apoptotic pathway. Using adenovirus-mediated gene transfer to 39 cancer cell lines, we found that EGR2 could induce apoptosis in a large proportion of these lines by altering the permeability of mitochondrial membranes, releasing cytochrome c and activating caspase-3, -8, and -9. Analysis by cDNA microarray and subsequent functional studies revealed that EGR2 directly transactivates expression of BNIP3L and BAK. Our results helped to clarify the molecular mechanism of the apoptotic pathway induced by PTEN-EGR2, and suggested that EGR2 may be an excellent target molecule for gene therapy to treat a variety of cancers..
14. Unoki M, Nakamura Y., Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway., Oncogene, doi:10.1038/sj.onc.1204608 , 20, 33, 4457-65, 2001.07, [URL], Defects in PTEN, a tumor suppressor, have been found in cancers arising in a variety of human tissues. To elucidate the tumor-suppressive function of this gene, we have been analysing expression profiles of cancer cells after introduction of exogenous PTEN. Those experiments identified 99 candidate genes that were transcriptionally transactivated. Among them, we report here the further analyses of eight genes, EGR2/Krox-20, BPOZ, APS, HCLS1/HS1, DUSP1/MKP1, NDRG1/Drg1/RTP, NFIL3/E4BP4, and a novel gene (PINK1, PTEN-induced putative kinase). Expression of six of them (PINK1, EGR2, HCLS1, DUSP1, BPOZ, and NFIL3) was decreased in ovarian tumors compared with corresponding normal tissues. Colony-formation assays using plasmid clones designed to express each gene indicated that EGR2 and BPOZ were able to suppress growth of cancer cells significantly; in particular, cancer-cell lines stably expressing BPOZ grew more slowly than control cells containing mock vector. Flow cytometry suggested that over-expression of BPOZ inhibited progression of the cell cycle at the G(1)/S transition. Anti-sense oligonucleotides for BPOZ or EGR2 effectively inhibited their expression, and cell growth was accelerated. Therefore both genes appear to be novel candidates as mediators of the PTEN growth-suppressive signaling pathway..
15. Unoki M, Furuta S, Onouchi Y, Watanabe O, Doi S, Fujiwara H, Miyatake A, Fujita K, Tamari M, Nakamura Y., Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene., Hum Genet., 10.1007/s004390000267, 106, 4, 440-6, 2000.04, [URL], Although intensive studies have attempted to elucidate the genetic background of bronchial asthma (BA), one of the most common of the chronic inflammatory diseases in human populations, genetic factors associated with its pathogenesis are still not well understood. We surveyed 29 possible candidate genes for this disease for single nucleotide polymorphisms (SNPs), the most frequent type of genetic variation, in genomic DNAs from Japanese BA patients. We identified 33 SNPs, only four of which had been reported previously, among 14 of those genes. We also performed association studies using 585 BA patients and 343 normal controls for these SNPs. Of the 33 SNPs tested, 32 revealed no positive association with BA, but a T924C polymorphism in the thromboxane A2 receptor gene showed significant association (chi2=4.71, P=0.030), especially with respect to adult patients (chi2=6.20, P=0.013). Our results suggest that variants of the TBXA2R gene or some nearby gene(s) may play an important role in the pathogenesis of adult BA..
主要総説, 論評, 解説, 書評, 報告書等
1. 鵜木元香, エピジェネティック制御因子の先天性変異, 医学のあゆみ, 2020.01, [URL].
2. 前之原 章司, 鵜木 元香, 領域特異的バイサルファイトシークエンシング, 実験医学別冊 エピジェネティクス実験スタンダード(牛島俊和・眞貝洋一・塩見春彦編集), 2017.05, [URL].
3. 鵜木 元香, 佐々木 裕之, エピジェネティック調節(DNAメチル化), 生体の科学 66 (特集) 細胞シグナル操作法, 474-475, 医学書院, 2015.09.
4. 鵜木 元香, 腎細胞癌とエピジェネティクス, Kidney Cancer No.3, 18-21, ノバルティスファーマ株式会社, 2014.12.
5. 鵜木 元香, 新田洋久, 佐々木 裕之, DNAメチル化酵素異常症, 遺伝子医学MOOK 25, 210-216, 2013.09, [URL], DNA中のシトシンのメチル化は安定なエピジェネティック情報であり、細胞種特異的な遺伝子発現、発生段階特異的な遺伝子制御、染色体の維持、レトロトランスポゾンの抑制、ゲノム刷り込みやX染色体不活性化などに重要である。細胞・組織に特異的なDNAメチル化パターンは初期発生において 新規メチル化酵素DNMT3AとDNMT3Bによって確立され、維持メチル化酵素DNMT1によってDNA複製・細胞分裂を経て伝達される。 DNMT3A ノックアウトマウスは生後4週までに死亡し、DNMT3B ノックアウトマウスおよびDNMT1ノックアウトマウスは胎生致死であることから、これらの酵素は個体の生存に必須である。本稿では、先天的および後天的なDNAメチル化酵素の異常症について述べる。.
6. Unoki M, Kumamoto K, Takenoshita S, Harris CC., Reviewing the current classification of inhibitor of growth family proteins., Cancer Sci., 2009.07, [URL].
7. Unoki M, Kumamoto K, Harris CC., ING proteins as potential anticancer drug targets., Curr Drug Targets., 2009.05, [URL], Recent emerging evidence suggests that ING family proteins play roles in carcinogenesis both as oncogenes and tumor suppressor genes depending on the family members and on cell status. Previous results from non-physiologic overexpression experiments showed that all five family members induce apoptosis or cell cycle arrest, thus it had been thought until very recently that all of the family members function as tumor suppressor genes. Therefore restoration of ING family proteins in cancer cells has been proposed as a treatment for cancers. However, ING2 knockdown experiments showed unexpected results: ING2 knockdown led to senescence in normal human fibroblast cells and suppressed cancer cell growth. ING2 is also overexpressed in colorectal cancer, and promotes cancer cell invasion through an MMP13 dependent pathway. Additionally, it was reported that ING2 has two isoforms, ING2a and ING2b. Although expression of ING2a predominates compared with ING2b, both isoforms confer resistance against cell cycle arrest or apoptosis to cancer cells, thus knockdown of both isoforms is critical to remove this resistance. Taken together, these results suggest that ING2 can function as an oncogene in some specific types of cancer cells, indicating restoration of this gene in cancer cells could cause cancer progression. Because knockdown of ING2 suppresses cancer cell invasion and induces apoptosis or cell cycle arrest, ING2 may be an anticancer drug target. In this brief review, we discuss possible clinical applications of ING2 with the latest knowledge of molecular targeted therapies..
8. Unoki M, Brunet J, Mousli M., Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis., Biochem Pharmacol., 2009.11, [URL], UHRF1 plays a central role in transferring methylation status from mother cells to daughter cells. Its SRA domain recognizes hemi-methylated DNA that appears in daughter DNA strands during duplication of DNA. UHRF1 recruits DNMT1 to the site and methylates both strands. UHRF1 also binds to HDAC1 and di- and tri-methyl K9 histone H3, ubiquitinates histone H3, and associates with heterochromatin formation, indicating that UHRF1 links histone modifications, DNA methylation, and chromatin structure. UHRF1 is a direct target of E2F1 and promotes G1/S transition. The tumor suppressor p53, which is deficient in 50% of cancers, down-regulates UHRF1 through up-regulation of p21/WAF1 and subsequent deactivation of E2F1. The expression levels of UHRF1 are up-regulated in many cancers, probably partially because of the absence of wild type p53, but it is probably regulated by several other factors. Knockdown of UHRF1 expression in cancer cells suppressed cell growth, suggesting that UHRF1 can be a useful anticancer drug target. Recently, it was revealed that UHRF1 plays important roles not only in carcinogenesis, but also in toxoplasmosis, which is occasionally fatal to people with a weakened immune system, and can cause blindness in the major pathology of ocular toxoplasmosis. Toxoplasma gondii, which causes toxoplasmosis, utilizes UHRF1 to control the cell cycle phase and enhance its proliferation. Thus, knockdown of UHRF1 can be effective at stopping the proliferation of the parasites in infected cells. In this review, we discuss several possible methods that can inhibit the multiple unique functions of UHRF1, which can be utilized for treating cancers and toxoplasmosis..
9. Motoko Unoki, Current and potential anticancer drugs targeting members of the UHRF1 complex including epigenetic modifiers., Recent Pat Anticancer Drug Discov., 2011.01, [URL], Epigenetic modulators play significant roles in carcinogenesis. DNA methylation and histone modifications are the two major epigenetic modifications involved in transcriptional regulation. Many histone modification enzymes and DNMTs are up-regulated in cancer cells, and contribute to malignant transformation. The majority of the current "new generation" of anticancer drugs target abnormally overexpressed oncogenic proteins such as kinases or receptors which mediate oncogenic signal transmission. Overexpression or accumulation of these oncoproteins in cancer is caused directly or indirectly by genetic or epigenetic abnormalities in tumor-associated genes. Among these changes, epigenetic changes in DNA and histones can be caused by aberrant expression of epigenetic modulator proteins in cells. Recently, it has been revealed that UHRF1, which is up-regulated in various cancers, links DNA methylation and histone modifications through binding to hemi-methylated DNA, and also to trimethylated histone H3K9. The UHRF1 complex includes HDAC1, Tip60, G9a, and maintenance and de novo DNMTs. Many of these are reported to be involved in carcinogenesis. Several anticancer drugs targeting epigenetic-machinery such as HDAC inhibitors, and DNMT inhibitors have been developed. Even though these drugs showed some effect on several types of cancer, mild to severe adverse reactions have been observed. In this article, the relevant patents on the strategies to develop safer anticancer drugs targeting epigenetic modulators, focusing on members and modifiers of the UHRF1 complex, are discussed..
主要学会発表等
1. 鵜木元香, 染色体の安定性はどのように維持されているのか?〜ICF症候群の原因遺伝子の機能解析から見えてきたこと〜, 加齢研研究員会セミナー, 2020.02, [URL].
2. 鵜木元香, 染色体の安定性はどのように維持されているのか?〜ICF症候群の原因遺伝子の機能解析から見えてきたこと〜, 浜松医科大学セミナー, 2020.02.
3. 鵜木元香, 染色体の安定性はどのように維持されているのか?〜ICF症候群の原因遺伝子の機能解析から見えてきたこと〜, ダイバーシティCHIBA研究環境促進コンソーシアム「スキルアップセミナー」, 2020.02.
4. 鵜木元香、船引宏則、佐々木裕之, ICF症候群の分子病態におけるCDCA7/HELLS複合体と非相同末端修復の関係性, 第37回染色体ワークショップ・第18回核ダイナミクス研究会, 2019.12.
5. Motoko Unoki, Hironori Funabiki, and Hiroyuki Sasaki, Role of the CDCA7/HELLS chromatin remodeling complex in genome stability, 第42回日本分子生物学会, 2019.12, [URL].
6. 鵜木元香、船引宏則、佐々木裕之, CDCA7/HELLSクロマチンリモデリング因子とNHEJ〜ICF症候群の分子病態の解明に向けて〜, 第25回DNA複製・組換え・修復ワークショップ, 2019.11, [URL].
7. Motoko Unoki, Hironori Funabiki, Hiroyuki Sasaki, Relationship between the CDCA7/HELLS chromatin remodeling complex and NHEJ in molecular pathogenesis of ICF syndrome, 第14回生命医科学研究所ネットワーク国際シンポジウム, 2019.10, [URL].
8. 鵜木元香, セントロメア・ペリセントロメア特異的維持メチル化機構の解明を目指して, 新学術領域研究「多様かつ堅牢な細胞形質を支える非ゲノム情報複製機構」 第1回領域会議, 2019.09.
9. Motoko Unoki, Hironori Funabiki, Hiroyuki Sasaki, Relationship between the CDCA7/HELLS complex and NHEJ in molecular pathogenesis of ICF syndrome, 第13回日本エピジェネティクス研究会年会, 2019.05, [URL].
10. 鵜木 元香, エピジェネティクスとがん, Tokyo Biomarker Seminar, 2019.05.
11. Motoko Unoki, CDCA7 and HELLS mutations undermine non-homologous end joining in centromeric instability syndrome, 第2回 九州大学女性研究者ダイバーシティシンポジウム, 2019.03.
12. 鵜木 元香, 船引 宏則, 佐々木 裕之, ICF症候群関連因子CDCA7とHELLSはKu80のDNA損傷部位への集積を促進し、非相同末端修復に関与する, 第41回日本分子生物学会, 2018.11, [URL].
13. Motoko Unoki, Hironori Funabiki, Hiroyuki Sasaki, ICF syndrome proteins CDCA7 and HELLS promote non-homologous end joining, 2018 Hot Spring Harbor symposium, 2018.10, [URL].
14. Motoko Unoki, Hiroyuki Sasaki, ICF syndrome proteins CDCA7 and HELLS promote non-homologous end joining, 日本人類遺伝学会第63回大会, 2018.10, [URL].
15. Motoko Unoki, Hironori Funabiki, Hiroyuki Sasaki, ICF syndrome proteins CDCA7 and HELLS promote non-homologous end joining, 2018 Cold Spring Harbor meeting: Epigenetics & Chromatin, 2018.09, [URL].
16. 鵜木 元香, ICF症候群の分子基盤:CDCA7はHELLSと結合し非相同末端結合型DNA修復を促進する, 第2回エピジェネティック因子の構造と機能をつなぐ会, 2018.09, [URL].
17. 鵜木元香, 佐々木裕之, ICF症候群の分子基盤:CDCA7はHELLSと結合し非相同末端結合型DNA修復を促進する, 第12回日本エピジェネティクス研究会年会, 2018.05, [URL].
18. 鵜木元香, ICF症候群の分子基盤〜DNA修復とエピジェネティック制御はつながるか? 〜, 発生研セミナー, 2018.05, [URL].
19. Motoko Unoki, Hiroyuki Sasaki, CDCA7, which is defective in ICF syndrome, is involved in DNA damage repair, The 2018 Cold Spring Harbor Asia Conference, 2018.04, [URL].
20. 鵜木 元香, 佐々木 裕之, エピジェネティック疾患ICF症候群の発症機序〜DNA修復機構の破綻と病態のリンク〜, 第40回日本分子生物学会年会(2017年度生命科学系学会合同年次大会), 2017.12, [URL].
21. 鵜木 元香, 佐々木 裕之, ICF症候群の分子基盤, 日本人類遺伝学会第62回大会, 2017.11, [URL].
22. Motoko Unoki, Hiroyuki Sasaki, ICF syndrome genes CDCA7 and HELLS are essential for DNA damage repair, France-Japan Epigenetics Workshop 2017, 2017.11, [URL].
23. 鵜木 元香, 佐々木 裕之, ICF症候群の分子基盤〜DNA修復機構の破綻とDNA脱メチル化 〜, 第11回日本エピジェネティクス研究会年会, 2017.05, [URL].
24. 鵜木 元香, DNA低メチル化を伴うICF症候群発症の分子基盤, 蛋白研セミナー「生命システムを支配するエピジェネティクス」, 2016.12.
25. 鵜木 元香, DNA低メチル化を伴うICF症候群発症の分子基盤の解明, 第1回 エピジェネティック修飾読み手分子の構造と生命機能をつなぐ会, 2016.09.
26. 鵜木 元香, UHRF1の同定からヒストンリジンの水酸化修飾の発見まで, 第16回 日本蛋白質科学会年会, 2016.06, [URL].
27. Shoji Maenohara, Motoko Unoki, Hidehiro Toh, Hiroaki Ohishi, Jafar Sharif, Haruhiko Koseki, Hiroyuki Sasaki, Essential role of Uhrf1 during oocyte growth and preimplantation development, the 4th Cold Spring Harbor Asia conference on Chromatin, Epigenetics and Transcription, 2016.05, [URL].
28. 鵜木 元香, 前立腺癌とゲノム・エピゲノム, 第13回 東京前立腺癌会議, 2016.02.
29. Motoko Unoki, Shoji Maenohara, Atsuo Ogura, Kimiko Inoue, Kazuo Yamagata, Hidehiro Toh, Hiroaki Ohishi, Jafar Sharif, Haruhiko Koseki, Koji Ueda, Hiroyuki Sasaki, Epigenetic regulator Uhrf1 plays a role in the oocyte cytoplasm that is essential for pre-implantation development, 第40回 内藤コンファレンス「エピジェネティクス―ヒストンコードから治療戦略へ」, 2015.09, [URL].
30. 鵜木 元香, エピジェネティクス制御機構の理解を目指して〜DNAメチル化結合タンパク質UHRF1の発見から今までとこれから〜, 生化学若い研究者の会, 2015.07.
31. 鵜木 元香, エピジェネ因子を標的とした新しい腎癌治療戦略〜既存薬の適応症例の拡大を目指して〜, 九大テクノロジーフォーラム, 2014.12.
32. 鵜木 元香, 腎癌とエピジェネティクス, Tokyo Votrient Forum for RCC 2014, 2014.06.
33. 鵜木 元香, 益田 晶子, 堂前 直, 新田 洋久, 前之原 章司, 福井 宣規, 白川昌宏, 中村祐輔, 佐々木 裕之, UHRF1相互作用タンパク質を介したエピジェネティック制御機構の解明を目指して, 第8回日本エピジェネティクス研究会年会 , 2014.05, [URL].
34. 鵜木 元香, 益田 晶子, 堂前 直, 福井 宣規, 中村 祐輔, 佐々木 裕之, JMJD6によるヒストンのリジン残基水酸化の発見, 第25回 高遠シンポジウム, 2013.08, [URL].
35. 鵜木 元香, 益田晶子, 堂前直, 佐々木 裕之, 高感度アミノ酸組成解析によるヒストンリジン残基の水酸化修飾の検出, 第7回日本エピジェネティクス研究会年会, 2013.05, [URL].
36. 鵜木元香、益田晶子、堂前直、福井宣規、有田恭平、浜本隆二、岩井裕希子、白川昌宏、佐々木裕之、中村祐輔, ヒストン水酸化酵素としてのJMJD6の同定, 日本遺伝学会, 2012.09.
37. 鵜木元香, エピジェネティック制御機構に関わるタンパク質相互作用の研究〜UHRF1から広がるエピジェネティクスネットワーク研究〜, 福島医学会学術研究集会シンポジウム NIRFが拓く医学の未来 福島で生まれた最新科学を世界へ(第1回 スタートアップ・シンポジウム), 2012.08.
38. 鵜木元香、益田晶子、堂前直、福井宣規、有田恭平、浜本隆二、岩井裕希子、白川昌宏、佐々木裕之、中村祐輔, In vivoにおけるヒストン水酸化酵素としてのJMJD6の同定, 第6回 エピジェネティクス研究会年会, 2012.05.
39. 鵜木元香、吉松正憲、有田恭平、益田晶子、堂前直、植田幸嗣、岩井裕希子、浜本隆二、白川昌宏、中村祐輔, UHRF1複合体に含まれるJMJD6によるヒストンリジン残基の水酸化について, 第5回 日本エピジェネティクス研究会年会, 2011.05.
40. 鵜木元香、醍醐弥太郎、鯉沼潤一郎、土屋永寿、浜本隆二、中村祐輔, UHRF1 is a novel molecular marker of lung cancer, 第69回日本癌学会学術総会, 2010.09.
41. 鵜木 元香, A novel epigenetic transcriptional regulation by UHRF1, which links histone modification and DNA methylation status, 第87回生医研・グローバルCOE理医連携セミナー, 2010.06, [URL].
42. Unoki M, Nakamura Y, Hamamoto R, JMJDX interacts with DEAH (Asp-Glu-Ala-His) box polypeptide 9 (DHX9), 101st American Association for Cancer Research (AACR) Annual Meeting, 2010.04.
43. Unoki M, Nakamura Y, Hamamoto R, UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer., 8th American Association for Cancer Research (AACR) /Japan Cancer Association (JCA) Joint International Conference, 2010.02.
44. 鵜木 元香、中村 祐輔、浜本 隆二, UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer, 第68回日本癌学会学術総会, 2009.10.
45. Unoki M, Hamamoto R, Nakagawa H, Nakamura Y, A novel demethylase candidate, JMJDX, physically associates with nucleolin, 100th American Association for Cancer Research (AACR) Annual Meeting , 2009.04.
46. 鵜木 元香、隈元 謙介、Harris CC , A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis, 第67回日本癌学会学術総会, 2008.10.
47. Unoki M, Shen JC, Zheng ZM, Harris CC, Identification of a novel splice variant of ING2, ING2b, 99th American Association for Cancer Research (AACR) Annual Meeting , 2008.04.
48. Unoki M, Shen JC, Zheng ZM, Harris CC, Regulation of Cell Growth and Motility by Novel Splice Variants of ING4, NIH-JSPS Symposium; Frontiers in 21st Century Biomedical Science: Highlights from Japan and the United States, 2007.11.
49. Unoki M, Harris CC, ING (INhibitor of Growth) Genes Are Candidate Tumor Suppressors, TEDCO/NIH/NCI Technology Showcase, 2007.09.
50. Unoki U, Shen JC, Zheng ZM, Harris CC, Novel splice variants of ING4 and their possible roles in regulation of cell growth and motility, 98th American Association for Cancer Research (AACR) Annual Meeting, 2007.04.
51. Unoki M, Shen JC, Zheng ZM, Harris CC, Identification of three novel splice-variants of a tumor suppressor candidate, ING4, 97th American Association for Cancer Research (AACR) Annual Meeting, 2006.04.
52. Motoko Unoki, Yusuke Nakamura, Methylation at CpG-islands in intron1 of EGR2 confers enhancer-like activity, 6th AACR/JCA Joint International Conference, 2004.02.
53. Unoki M, Nakamura Y, EGR2 induces apoptosis in various cancer-cell lines by direct transactivation of BNIP3L and BAK, 94th American Association for Cancer Research (AACR) Annual Meeting, 2003.04.
54. 鵜木元香、中村祐輔, Transcriptional regulation of EGR2 that induces apoptosis in PTEN signaling pathway, 第62回日本癌学会学術総会, 2003.10.
55. 鵜木元香、中村祐輔, Molecular mechanism of the apoptosis pathway induced by PTEN-EGR2, 第61回日本癌学会学術総会, 2002.10.
56. 鵜木元香、中村祐輔, Functional analyses of PTEN and its down stream genes, BPOZ and EGR2, 第60回日本癌学会学術総会, 2001.10.
57. Unoki M, Nakamura Y, Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway, The 8th East Asian Joint Symposium on Biomedical Research, 2001.07.
58. 鵜木元香、中村祐輔, Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway, 第28回東京大学医科学研究所創立記念シンポジウム , 2001.06.
59. Unoki M, Nakamura Y, Expression Profile and Functional Analyses of Genes Induced in Endometrial Cancer Cells Expressing Exogenous PTEN, 5th AACR/JCA Joint International Conference, 2001.02.
60. 鵜木元香、中村祐輔, Microarray Analysis of Gene-Expression Profiles in Endometrial-Cancer Cells Transfected with Exogenous PTEN, 第59回日本癌学会学術総会, 2000.10.
学会活動
所属学会名
日本遺伝学会
日本人類遺伝学会
日本分子生物学会
エピジェネティクス研究会
アメリカ癌学会
日本癌学会
学会大会・会議・シンポジウム等における役割
2019.12.06~2016.06.09, 第42回日本分子生物学会, ワークショップ オーガナイザー.
2019.11.09~2019.11.11, 第25回DNA複製・組換え・修復ワークショップ, 座長(Chairmanship).
2018.09.04~2018.09.05, 「第2回 エピジェネティック因子の構造と機能をつなぐ会」, 事務・運営.
2017.12.09~2017.12.09, 2017年度生命科学系学会合同年次大会(ConBio2017), 座長(Chairmanship).
2016.12.21~2016.12.21, 蛋白研セミナー「生命システムを支配するエピジェネティクス」, 座長(Chairmanship).
2016.09.13~2016.09.13, 「第1回 エピジェネティック修飾読み手分子の構造と生命機能をつなぐ会」, 座長(Chairmanship).
2016.06.09~2016.06.09, 第16回日本蛋白質科学会年会ワークショップ, 座長(Chairmanship).
2016.11.02~2016.11.03, 第26回ホットスプリングハーバー国際シンポジウム, 事務・運営.
2016.06.09~2016.06.09, 第16回日本蛋白質科学会 , ワークショップ オーガナイザー.
2014.10.31~2014.11.01, 生殖細胞のエピゲノムダイナミクスとその制御 第2回領域シンポジウム, 運営・事務.
2011.08.05~2011.08.06, 第6回 GCOE 理医連携リトリート, 座長(Chairmanship).
2010.11.22~2010.11.24, International symposium on epigenome network, development, and reprograming of germ cells, 運営・事務.
学術論文等の審査
年度 外国語雑誌査読論文数 日本語雑誌査読論文数 国際会議録査読論文数 国内会議録査読論文数 合計
2019年度 12        12 
2018年度      
2017年度      
2016年度      
2015年度      
2014年度      
2013年度      
2012年度      
2011年度 10        10 
2010年度      
2009年度      
2008年度      
その他の研究活動
海外渡航状況, 海外での教育研究歴
National Cancer Institute, NIH, UnitedStatesofAmerica, 2004.05~2008.04.
受賞
The 40th Naito Conference Best poster award, 内藤記念科学振興財団, 2015.09.
第25回高遠シンポジウム優秀ポスター賞, 2013.08.
研究資金
科学研究費補助金の採択状況(文部科学省、日本学術振興会)
2019年度~2023年度, 新学術領域研究(研究領域提案型), 分担, DNAメチル化によるゲノム情報安定化機構の解明.
2018年度~2020年度, 基盤研究(C), 代表, ICF症候群の分子病態基盤:新しいエピゲノム安定維持機構の解明を目指して.
2015年度~2017年度, 基盤研究(C), 代表, 配偶子形成過程および初期発生におけるUHRF1の役割の解明 .
2012年度~2014年度, 基盤研究(C), 代表, ゲノムインプリンティングにおいてUHRF1が果たす役割の解明.
2010年度~2011年度, 若手研究(B), 代表, UHRF1が関わる新規ヒストン修飾についての機能解析 .
日本学術振興会への採択状況(科学研究費補助金以外)
2001年度~2002年度, 特別研究員, 癌抑制遺伝子PTENの下流遺伝子の単離と機能解析.
2003年度~2003年度, 特別研究員, 癌抑制遺伝子PTENの下流遺伝子の単離と機能解析.
2004年度~2005年度, 海外特別研究員, 癌抑制遺伝子p53の下流遺伝子 の同定と機能解析.
寄附金の受入状況
2019年度, 山田科学振興財団, 2019年度 研究援助.
2015年度, 内藤記念科学振興財団, 内藤記念特定研究助成金.
2011年度, 武田科学振興財団, 武田科学振興財団/新規メチル化DNA結合タンパク質の同定.
学内資金・基金等への採択状況
2017年度~2017年度, 国際学会派遣支援, 代表, ICF syndrome genes CDCA7 and HELLS are essential for DNA damage repir.
2017年度~2017年度, 平成29年度 QRプログラム・わかばチャレンジ, 代表, ICF症候群の原因遺伝子CDCA7とHELLSの機能解析から迫る新しいDNA脱メチル化機構の解明.
2012年度~2012年度, 平成24年度 九州大学教育研究プログラム・研究拠点形成プロジェクト, 代表, ヒストンのリジン残基 「水酸化」の生理的意義の解明.
2011年度~2011年度, 平成23年度九州大学教育研究プログラム・研究拠点形成プロジェクト, 代表, 「エピジェネティックな遺伝子発現制御機構」及び「ヒストンの修飾継承機構」「ゲノムインプリンティング機構」にUHRF1が果たす役割の解明.

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。
 
 
九州大学知的財産本部「九州大学Seeds集」